Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.
Foresti
V
V
D000368:Aged; D000369:Aged, 80 and over; D000536:Aluminum Hydroxide / Q000008:administration & dosage / Q000009:adverse effects*; D002411:Cation Exchange Resins / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D006947:Hyperkalemia / Q000188:drug therapy; D007415:Intestinal Obstruction / Q000139:chemically induced*; D007676:Kidney Failure, Chronic / Q000188:drug therapy; D008297:Male; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects*; D011137:Polystyrenes / Q000008:administration & dosage / Q000009:adverse effects*; D012117:Resins, Synthetic / Q000008:administration & dosage / Q000009:adverse effects*; D014277:Trigeminal Neuralgia / Q000188:drug therapy
D002411:Cation Exchange Resins; D011137:Polystyrenes; D012117:Resins, Synthetic; D000536:Aluminum Hydroxide; C003321:polystyrene sulfonic acid; D009020:Morphine